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Abstract
Background: The repair of single base mutations in mammalian genes can be directed by single-
stranded oligonucleotides in a process known as targeted gene repair. The mechanism of this
reaction is currently being elucidated but likely involves a pairing step in which the oligonucleotide
align in homologous register with its target sequence and a correction step in which the mutant
base is replaced by endogenous repair pathways. This process is regulated by the activity of various
factors and proteins that either elevate or depress the frequency at which gene repair takes place.
Results: In this report, we find that addition of selenomethionine reduces gene repair frequency
in a dose-dependent fashion. A correlation between gene repair and altered cell cycle progression
is observed. We also find that selenium induces expression of Ref-1 which, in turn, modifies the
activity of p53 during the cell cycle.
Conclusion:  We can conclude from the results that the suppression of gene repair by
introduction of selenomethionine occurs through a p53-associated pathway. This result indicates
that the successful application of gene repair for treatment of inherited disorders may be hampered
by indirect activation of endogenous suppressor functions.
Background
Targeted gene repair is a process that corrects single base
mutations in genes within the chromosome. Nucleotide
alteration is directed by a short single-stranded oligonu-
cleotide, which also serves as a template for the base
exchange reaction. The mechanism of action continues to
be unraveled but the general system involves a DNA pair-
ing step in which the oligonucleotide aligns to the homol-
ogous target site and a correction step in which the genetic
information in the oligonucleotide is transferred to the
target gene [1,2]. The reaction is catalyzed by enzymes
involved in homologous recombination and may be
influenced by proteins that regulate the cellular response
to DNA damage [3-6]. Damage occurs naturally in mam-
malian genomes by the action of oxygen radicals, mis-
takes in DNA synthesis and from exogenous sources such
as chemicals or irradiation.
Chemotherapeutic drugs such as VP16 or camptothecin
(CPT) or reagents such as hydroxyurea, thymidine, or
methyl methanesulfonate (MMS) that cause lesions to
accumulate at replication forks [7-10] can be used to
induce DNA damage in experimental systems and facili-
tate studies of gene repair. These lesions inhibit fork
movement, leading to a stall in S phase, an event that
stimulates gene repair activity. In a recent study, Hu et al.
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[11] found that the synchronization of cells at the G1/S
border with subsequent release enables a higher level of
gene repair. The correction levels peak when the majority
of cells are in S phase, results which align with earlier data
of Majumdar et al. [12]. In addition, Brachman and Kmiec
[13,14] demonstrated that DNA replication can influence
both the rate and frequency of gene repair. By slowing fork
movement, these workers were able to elevate the fre-
quency by activating the homologous recombination
(HR) pathway and enabling the correction process to
occur with greater efficiency. These data are consistent
with earlier reports that had already pointed to HR as a
regulatory process of gene repair [4,10]. The induction of
HR pathways by DNA damage and the subsequent stimu-
lation of gene repair has provided further clarification of
the proteins and pathways involved in the correction
events. While earlier findings support a role for DNA dam-
age-induced responses in elevating the frequency of gene
repair, little is known about the mechanism of correction
i.e. the details of nucleotide exchange. What is known is
that regulatory proteins activated by DNA damage events
stimulate a cellular response that leads directly or indi-
rectly to a high efficiency of gene repair activity.
The p53 tumor suppressor regulates cell cycle check-
points, apoptosis, and can transactivate a number of genes
involved DNA repair. Furthermore, p53 can act to sup-
press HR; it is recruited to stalled replication forks to slow
or prevent uncontrolled homologous exchanges [15-17].
When p53 was overexpressed in DLD-1 cells simultane-
ous with the initiation of oligonucleotide-directed gene
repair, p53 acts as an antagonist of the reaction, reducing
the level of eGFP positive, corrected cells significantly
[13]. This suppressive activity could result from p53's role
in cell cycle control, DNA damage response, or regulation
of senescence and apoptosis. As a long term goal, we seek
to modulate and harness the HR repair response as it
relates to gene repair activity without inducing the natural
suppression associated with the induction of DNA dam-
age.
The amino acid selenomethionine, the major component
of Se-enriched foods, has long been demonstrated as a
chemopreventative agent, and selenium compounds have
yielded encouraging results in current clinical trials to pre-
vent prostate, colon, and other human cancers. Selenom-
ethionine has been reported to induce a DNA repair
response and enhance repair-complex formation in
treated cells by means of a modulation of p53 activity
[18]. The tumor-suppressor function of p53 is usually
attributed to its activity at a post-damage stage when it
eliminates cells with damaged DNA resulting from geno-
toxic stress. Selenomethionine seems to induce a different
branch of p53 activity, converting p53 into a new confor-
mation through a reduction reaction catalyzed by the pro-
tein Ref-1. In this form, p53 does not have any growth-
suppressing effect but can effectively modulate DNA
repair. Thus, p53 facilitates control over genomic stability
by a mechanism that does not require cell death or arrest
[18,19]. An agent that modulates gene repair without
exhibiting toxicity or inducing DNA damage has numer-
ous advantages, particularly in cases where the level of
repair falls below that of clinical relevance and an adju-
vant treatment will be required.
Ref-1 is important for the redox regulation of p53, but it
is also involved in a number of critical cellular pathways.
Ref-1 associates with the human Ape1 protein, forming
the multifunctional human AP endonuclease (Ape1/Ref-
1). Ape1-Ref-1 functions as an AP endonuclease in DNA
repair, and it can activate numerous transcription factors
through redox-dependent and redox independent mecha-
nisms [20]. Ref-1 exerts redox control of p53 protein by
reducing adjacent cysteine residues (at position 275 and
277 respectively), breaking the disulfide bond and render-
ing a new p53 conformation. This conformation is associ-
ated with increased activation of DNA repair proteins,
thus requiring less action for cell cycle arrest or apoptosis.
As described above, selenomethionine has been reported
to induce a DNA repair response and enhance repair-com-
plex formation in treated cells. We have reported how to
create such a response by inducing a tolerable level of
DNA damage that elevates gene repair activity [5,6,21]. In
order to advance the technology of gene repair in disease
models it is necessary to develop safe and simple methods
to increase the efficiency of this repair. Selenium com-
pounds clearly influence DNA damage response pathways
[22] often modulating the levels of enzymes known to be
involved in gene repair. It should be noted that these
authors focused on nucleotide excision repair, a process
unrelated to homologous recombination. In any event,
we examined the effect of selenium on gene repair activity
in a mammalian model cell system in order to gain a
greater perspective on the degree of cellular response to
the activation of repair pathways.
Results
The assay system
A standard assay system based on the correction of an
integrated mutant eGFP gene was employed to measure
gene repair activity. A single clonal isolate from HCT 116
cells (which contain the wild-type complement of p53
genes) containing a single copy of the mutant eGFP gene
(which is actively transcribed in these cells) was used for
these experiments. A low-copy target gene is advantageous
in a model system for oligonucleotide-directed gene
repair, conferring only a single site for gene repair activity
per cell. Specific oligonucleotides were designed to correct
the TA G point mutation at amino acid position 67 which
lies in the chromophore region of the eGFP gene and con-
version to TA C enables expression of wild-type eGFP,BMC Molecular Biology 2007, 8:7 http://www.biomedcentral.com/1471-2199/8/7
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allowing detection of positive conversion events by FACS
analysis [11] (see Figure 1A). The standard vector,
EGFP3S/47NT, is a 47-mer containing three phospho-
rothioates at each termini to protect against nuclease
activity. This system is well established and has been used
in multiple studies to validate gene repair activity
[5,6,11,13,23].
Selenomethionine does not induce cell toxicity
We examined cellular toxicity and genotoxicity of sele-
nium in the HCT 116 model system. In general, organic
selenium compounds have been found to exhibit low lev-
els of toxicity in most cells. In our hands, selenomethio-
nine was found to be nontoxic in HCT 116 cells, as
measured by an MTT reduction assay for viability with
concentrations up to 1 mM (see Figure 1B). These results
set the viability parameters and indicate that a 24 h pre-
treatment with 50–200 μM selenomethionine, the experi-
mental conditions used traditionally to assess the
modulation of gene repair activity, does not lead to signif-
icant cell death.
Selenomethionine does not induce double-stranded breaks 
in DNA
At the genomic level, no significant DNA breakage in HCT
116 cells is observed by the addition of selenomethionine
as evidenced by the pulse field gel (PFGE) presented in
Figure 1C. Genomic DNA isolated from selenomethio-
nine-treated cells at concentrations of 100, 200, and 400
μM respectively does not exhibit greater fragmentation
compared to an untreated population of cells. This is in
sharp contrast to the positive control in which the cells
were treated with methyl methanesulfonate (150 μM)
[24]. In this case, significant fragmentation is observed,
evidenced by the bright smear of DNA containing an
extensive number of breaks running into the gel. The
bright band near the top of the damaged DNA region rep-
resents genomic DNA containing only a few strand
breaks. Thus, selenomethionine treatment does not result
in extensive DNA damage and therefore does not induce
a cellular DNA repair response similar to that seen when
etoposide (VP16) or camptothecin is added to a cell cul-
ture [25].
Gene repair activity modulated by selenomethionine
Recently, we reported that inducing a low level of DNA
damage in cells significantly elevates the level of gene
repair activity [5,6]; the introduction of double strand
breaks in the target cell led to a cell cycle arrest in response
to the creation and/or presence of the DNA damage. Dur-
ing the arrested phase of the reaction, the oligonucleotide
is able to more accurately and efficiently gain access to the
target site on the DNA, presumably because the cells
undergoing gene repair are contained within the popula-
tion suspended in S phase [see 26 for review]. One
response to DNA damage is the elevation of activities
which have been shown previously to regulate the gene
repair reaction. Thus, agents that increase repair activity
are obvious candidates for stimulatory factors of correc-
tion, and particularly those that stimulate the repair path-
ways without causing DNA damage. Along these lines,
selenomethionine has been shown to induce DNA repair
processes by stabilizing the formation of repair complexes
[27]. Thus, we tested for modulation of gene repair by pre-
treating the cells with varying doses of selenomethionine.
The cells were treated for twenty-four hours, followed first
by a wash-out and electroporation of the oligonucleotide,
EGFP3S/47NT. Gene repair was evaluated by FACS
twenty-four hours later, and the data reveal that correction
levels decrease as a function of dose of selenomethionine
(50, 100, and 200 μM, respectively) (Figure 2A). These are
the same concentrations (described above) that exhibit no
significant cytotoxicity (see Figure 1B).
The effect of selenomethionine treatment on cell cycle 
progression
As mentioned above, some treatments that increase the
efficiency of gene correction do so by inducing DNA dam-
age and cell cycle arrest [26]. Other treatments induce S
phase accumulation but without DNA damage and still
support high levels of gene repair [13,14]. Since selenom-
ethionine has not been reported to damage DNA directly
and we observed no ds breaks (see Figure 1C), we exam-
ined the effect of selenomethionine pretreatment on cell
cycle progression. As shown in Figure 2B, cells treated
with selenomethionine for 24 hrs exhibit a different cell
cycle profile compared to untreated cells. FACS analysis
reveals that while the overall percentage of cells in S phase
is the same for non-treated and selenomethionine-treated
cells, selenomethionine-treated cells exhibit some accu-
mulation in G2 with a compensatory reduction in the
population of cells in G1 or at the G1/S border. This result
is similar to a cell cycle block caused by oxidative damage,
where the passage from G2 to mitosis is delayed [28].
Thus, selenomethionine does not arrest or delay cells in S
phase, a condition that has been shown to stimulate gene
repair activity. Interestingly, the effect on cell cycle is
reversible, as the cell cycle profile of treated cells returns to
normal 24 hours after the removal of selenomethionine
from the culture (Figure 2B).
Selenomethionine does not lead to increased expression or 
activation of p53 but does increase Ref-1 levels
As shown in Figure 2A, selenium reduces gene repair activ-
ity. One may therefore predict that this reduction is trans-
mitted through a Ref-1-mediated redox activation of wild-
type p53 [18], which has been shown to suppress gene
repair activity [13]. As such, selenomethionine treatment
should not increase the overall expression of p53 in
HCT116 cells, nor should it induce the activation of p53BMC Molecular Biology 2007, 8:7 http://www.biomedcentral.com/1471-2199/8/7
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(A). Map of mutant eGFP gene, integrated in HCT 116 cells Figure 1
(A). Map of mutant eGFP gene, integrated in HCT 116 cells. The wild-type and mutant sequence of the eGFP gene, where the 
point mutation is in the eGFP cassette, TAG, are shown above (base is in bold and underlined). This is the target for the 47-
mer oligonucleotide, EGFP3S/47NT, directed to the non-transcribed strand of the eGFP gene. EGFP3S/47NT is a single-
stranded oligonucleotide with three phosphorothioate modifications on each terminus. (B). Selenomethionine is not cytotoxic in 
HCT 116 cells. Cells were incubated with selenomethionine at concentrations of 0, 50, 200, 400, and 1000 μM, respectively. 
Viability was determined by an MTT-reduction assay; each data point represent mean of three (± S.D.), non-treated cells are 
normalized to 100% viable. (C). Exposure to selenomethionine does not induce DSBs in HCT 116 cells. Cells were grown with 
respective treatment for 24 hours prior to harvesting and prepared for pulsed-field gel electrophoresis (PFGE). The gel was 
run for 24 hrs and subsequently stained with ethidium bromide. Lane M, S. cerevisiae chromosomal DNA size marker presented 
in kilobases; Lane C, non-treated control HCT 116 genomic DNA; Selenmethionine-treated (100 μM, 200 μM, 400 μM) HCT 
116 cells; Lane MMS, MMS (150 μM) -treated HCT 116 genomic DNA.
Mutant eGFP
5’-ACCCTCGTGACCACCCTGACCTA GGGCGTGCAGTGCTTCAGCCGCTA-3’
3’-TGGGAGCACTGGTGGGACTGGATCCCGCACGTCACGAAGTCGGCGAT-5’
Wild type eGFP
5’-ACCCTCGTGACCACCCTGACCTA CGGCGTGCAGTGCTTCAGCCGCTA-3’
3’-TGGGAGCACTGGTGGGACTGGATGCCGCACGTCACGAAGTCGGCGAT-5’
EGFP3S/47NT
5’-T*A*G*CGGCTGAAGCACTGCACGCCGTAGGTCAGGGTGGTCACGAG*G*G*T-3’
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R/Neo
R PSV40
Poly A CMV mut eGFP SV40 Poly A F1 ori
0
20
40
60
80
100
0 100 200 300 400 500 600 700 800 900 1000
Selenomethionine (µM)
%
 
V
i
a
b
i
l
i
t
y
MC
Selenomethionine
100 µM 200 µM 400 µM 150 µM
MMS
Kb
1900 + 
1640
1120 + 
1100
B
A
CBMC Molecular Biology 2007, 8:7 http://www.biomedcentral.com/1471-2199/8/7
Page 5 of 10
(page number not for citation purposes)
through phosphorylation. We tested this prediction by
western blot analysis of proteins isolated from HCT116
cells treated with selenomethionine (200 μM) for 24
hours (Figure 3). An immunoblot with the p53-DO anti-
body, which is specific for total wild-type and mutant
p53, exhibited no distinguishable change in p53 expres-
sion in non-treated or selenomethionine-treated cells.
Likewise, immunoblotting with an antibody specific to an
activated form of p53 (phosphorylation of serine-15)
[29,30], which occurs in response to DNA damage
showed no detectable activated p53 in the non-treated
and selenomethionine-treated cells.
Whereas p53 levels are unchanged in the presence of
selenomethionine, the Ref-1 protein is present at higher
levels in HCT116 after 24 hrs treatment with selenome-
thionine (200 μM), as determined by immunoblot spe-
cific to Ref-1 (Figure 3). This supports our hypothesis that
selenomethionine may reduce gene repair activity
through p53 modification that is mediated by the Ref-1
protein.
Effect of p53 overexpression (wild-type and mutant) in 
human cell lines
Wild-type or mutant p53 overexpression plasmids were
introduced to cells in the presence of selenomethionine
with simultaneous introduction of the targeting oligonu-
cleotide. 5 μg of respective p53 overexpression plasmid
and EGFP3S/47NT oligonucleotide were electroporated
and evaluated by FACS after 24 hours. As displayed in Fig-
ure 4A, cells transfected with the pcDNA empty plasmid
and selenomethionine exhibit a reduction in gene repair
activity. This result is equivalent to suppression of gene
repair activity found in cells transfected with the p72 plas-
mid, which overexpresses wild-type p53. In combination,
selenomethionine treatment in the presence of over-
expressed p53 exacerbates this effect further, resulting in a
nearly undetectable level of correction. Thus, selenome-
thionine-dependent redox control of endogenous p53
appears to act synergistically with elevated levels of p53 in
the suppression of gene repair.
To explore the role of p53 in this reaction, we utilized a
separate cell line that has been used previously as an assay
system for gene repair activity. This cell line, DLD-1 [11]
contains the same mutated eGFP gene as the HCT116 line
used above in low copy number. Using a cell line with a
low copy number of integrated targets is important in
studies related to gene repair. In addition, this line does
not have a full complement of p53 [see 14]. Using the
same reaction protocol as carried out for experiments in
HCT116 cells, the integrated DLD-1 cell line was electro-
(A). Selenomethionine treatment suppresses gene repair Figure 2
(A). Selenomethionine treatment suppresses gene repair. HCT 116 cells were treated with selenomethionine (50 μM, 100 μM, 200 
μM) for 24 hours prior to electroporation of the oligonucleotide. The cells were analyzed by FACS 24 hours after electropo-
ration. The data represents three (± S.D.) independent experiments. (B). Selenomethionine induces mild, reversible G2/M delay. 
HCT 116 cells were not treated or treated with selenomethionine (50 μM, 200 μM) for 24 hours and processed for analysis of 
cell cycle. The profiles were generated using ModFit LT software. For cells treated with selenomethionine for 24 hrs: no treat-
ment (57.6 +/- 1.4%G1, 26.1 +/- 0.6%S,16.37 +/- 0.8% G2), 50 μM selenomethionine (50.7 +/- 1.6% G1,24.7 +/- 1.3%S,24.6 +/- 
2.6% G2) 200 μM selenomethionine (43.8 +/- 2.27% G1,20.1 +/- 3.9% S,36.1 +/- 6.2 % G2). For cells treated with selenome-
thionine for 24 hrs, washed, and allowed to recover for 24 hrs: no treatment (55.2 +/- 3.3% G1,28.8+/- 1.8S,16.1 +/- 1.4%G2), 
50 μM selenomethionine (50.8 +/- 2.9% G1, 29.8+/- 3.3% S,19.4+/- 0.4%G2) 200 μM selenomethionine (53.2 +/- 1.2% G1, 
31.7+/- 1.9% S,15.1+/- 0.7 G2).
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porated with EGFP3S/47NT and the appearance of cor-
rected cells viewed 24 hours later. Some samples were pre-
incubated with the indicated concentration of selenome-
thionine for 24 hours prior to electroporation. As shown
in Figure 4B, selenomethionine does not induce an inhi-
bition of gene repair; in fact a slight but reproducible stim-
ulation is seen in a dose-dependent fashion. Thus, a cell
line devoid of the full complement of wild-type p53
responds differently to treatment with selenomethionine
than does a cell line containing wild-type p53.
Discussion and conclusion
The product of the tumor suppressor gene, p53, down-reg-
ulates the process of homologous recombination [17,31].
The protein may act upon enzymes involved in the DNA
damage response pathway or act directly at crossover junc-
tions, effectively stalling their development. Since the
process of gene repair requires the activity of proteins
involved in HR, we might predict that events that induce
HR suppression would likewise result in a reduction in the
frequency of gene repair. Previous work in our laboratory
[13] and others demonstrated that wild-type p53 can act
as an antagonist of the gene repair reaction, whereas over-
expression of some mutant p53 proteins exhibit a small
yet significant elevation in the frequency of gene repair
[13]. The suppressive action of wild-type p53 [17] may
affect the gene repair reaction through the binding to rep-
lication forks which have been shown to be a key interme-
diate (and in fact a stimulant) in the correction process
[26].
We observe that the overexpression of wild-type p53 gene
in HCT116 leads to a reduction in gene repair, confirming
data from Pierce et al. [32] and Brachman et al. [13]. The
study by Pierce et al. utilized cell-free extracts as sources of
gene repair activity while Brachman and Kmiec tested p53
overexpression directly in cells [13]. The inhibitory effect
of p53 in DLD-1 cells which contain both mutant and
wild-type alleles was clearly evident. Mutations in the
DNA binding domain of the p53 gene can cause the p53
protein to lose the ability to suppress homologous recom-
bination [31,33,34]. Mutant forms of p53 may not be able
to inhibit Rad51-mediated strand exchange or the reverse
branch migration of stalled replication forks [17,35].
Expression of several mutant p53 proteins, specifically,
the p53 175H mutant, which inhibits G1 checkpoint con-
trol, can prevent the suppression of HR and stimulate rep-
lication inhibition-induced HR [9,15]. Here, we utilize
HCT116 cells that have a normal genetic complement of
wild-type p53 genes and show that additional p53 sup-
presses the frequency of gene repair even further.
Our data suggest that suppression of gene repair activity
most likely does not occur through an elevation in p53
expression nor by the activation of a well-known p53 con-
former. Thus, we explored a novel explanation for the sup-
pressive nature of selenomethionine in the gene repair
reaction [20,36], showing that the addition of selenome-
thionine (SeMet) to HCT116 cells leads to a reduction in
gene repair activity. Selenium compounds have been
shown to elevate p53 activity [37,38] and to stimulate
Selenomethionine treatment does not result in great levels of expressed or activated p53 Figure 3
Selenomethionine treatment does not result in great levels of expressed or activated p53. HCT 116 cells were not treated or treated 
with selenomethionine (200 μM) for 24 hours prior to protein isolation. Western blot analysis reveals that expression of wild-
type p53 is unchanged in the presence of selenomethionine; activation of p53 by serine-15 phosphorylation does not occur in 
the presence of selenomethionine; p53 is phosphorylated at serine-15 when cells are treated with camptothecin (CPT; 30 nM) 
for 24 hours; it serves here as a positive control.
Ref-1
Actin
SeMet (µM):
HCT
0             200
Total p53
phosphorylated(ser-15) p53 CPTBMC Molecular Biology 2007, 8:7 http://www.biomedcentral.com/1471-2199/8/7
Page 7 of 10
(page number not for citation purposes)
DNA damage response pathways through a phosphoryla-
tion cascade that includes ATM and H2AX [22]. Gene
repair activity has been shown to be sensitive to the activ-
ities of proteins involved in the response to DNA damage
[13,14]. Thus, it was of interest to determine which sele-
nium-induced pathway would predominate in this sys-
tem; would increased DNA repair activities promote
correction or would induction of p53 lead to suppression.
We observed that gene repair is possibly inhibited by a
pathway involving p53. This pathway includes Ref-1
which controls the activity of p53 through redox activa-
tion [20]. Ref-1 is also a key protein in the activation of
other proteins including transcription factors and
enzymes involved in nucleotide excision repair [20].
While the downstream effects of Ref-1 induction are
numerous, we focused on the activation of the Ref-1 pro-
tein by SeMet. We show that under conditions that pro-
mote gene repair, SeMet induces Ref-1 expression with a
concurrent diminution of correction. The reduction by
SeMet aligns with the effect of p53 overexpression (Figure
4A and 4B) and the two appear to act synergistically.
Taken together, these data suggest that inhibition of gene
repair by SeMet most likely takes place in a pathway
involving Ref-1. The most likely downstream target for
Ref-1, especially in response to DNA damage is p53. Thus,
consistent with the previous reports, we believe that p53
plays a critical, if not suppressive role, in regulating the
frequency of gene repair.
Our data are consistent with a role for homologous
recombination in the mechanism of gene repair [26]. A
number of key proteins are involved in modulating the
frequency of correction. These include Rad51, Rad52 and
Rad57 [39] as well as ATM, CHK1 and CHK2 [40]. Based
on the data presented herein, we can conclusively add p53
to that list. This protein can inhibit homologous recombi-
nation functions by binding to the three-stranded recom-
bination intermediate and destabilizing it [35,41]. As
shown by Drury et al. [42], the three-stranded intermedi-
ate is a requisite structure in the gene repair pathway and
thus one can envision that p53 suppression activity occurs
through the destabilization of structural intermediates.
Alternatively, the activation of p53 by selenomethionine,
mediated by Ref-1, could inhibit the progression of repli-
cation forks, by enabling fork regression [17,43]. This
reversal reduces the number of targets for gene repair
(A). Suppression of gene repair by p53 overexpression is equivalent to selenomethionine treatment Figure 4
(A). Suppression of gene repair by p53 overexpression is equivalent to selenomethionine treatment. Cells were incubated with or 
without 200 μM selenomethionine for 24 hrs. 5 μg of respective overexpression plasmid (empty plasmid (pcDNA), wild-type 
p53 (P72), or mutant p53 (R175H)) and 8 μM EGFP3S/47NT oligonucleotide was electroporated in HCT 116 cells; gene repair 
levels were evaluated by FACS after 24 hours. (B). Selenomethionine treatment enhances gene repair in DLD-1 (p53+/- mutant). 
DLD-1 cells were treated with selenomethionine (50 μM, 100 μM, 200 μM) for 24 hours prior to electroporation of the oligo-
nucleotide. The cells were analyzed by FACS 24 hours after electroporation. The data represents three (± S.D.) independent 
experiments.
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because correction events rely heavily on the process of
DNA replication [26]. Thus, induction of p53 activity will
remain a barrier to the successful application of gene
repair as therapy for genetic disorders.
Methods
Cell line and culture conditions
The HCT 116 cell line was acquired from ATCC (American
Type Cell Culture, Manassas, VA). The HCT 116 was cre-
ated by the integration of a pEGFP-N3 vector (Clontech,
Palo Alto, CA) containing a mutated eGFP gene, as
described by Hu et al. [11]. A nonsense mutation at posi-
tion +67 results in nonfunctional eGFP protein; the oligo-
nucleotide directs the conversion of the stop codon to a
tyrosine (wild-type eGFP), allowing the expression of
functional eGFP. HCT 116 cells were grown in McCoy's
5A Modified medium (Sigma-Aldrich, St. Louis, MO) and
10% fetal bovine serum. The mutant eGFP gene target was
integrated into these cells and a clonal line containing a
single copy was isolated by neo-selection (Geneticin,
GIBCO, Invitrogen, Carlsbad, CA). DLD-1 integrated cell
line was created and transfected as described by Hu et al.
[11].
Selenomethionine treatment
Cells were seeded at a density of 1.5 × 106 in a 100 mm
dish in complete medium supplemented with 10% FBS
and desired concentration of selenomethionine (Sigma-
Aldrich, St. Louis, MO) 24 h prior to electroporation of
the oligonucleotide. All cells were washed twice in 1X PBS
(GIBCO, Invitrogen, Carlsbad, CA) immediately prior to
harvesting for electroporation.
MTT viability assay
Sensitivity to selenomethionine was analyzed by a 3- [4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT, Sigma-Aldrich, St. Louis, MO) viability assay. Cells
were plated in a 24-well plate at a density of 1 × 105 cells
per well using complete medium supplemented with 10%
FBS and selenomethionine at concentrations of 50, 200,
400, and 1000 μM, respectively. After 24 hours of treat-
ment, cells were washed in PBS and 500 μl (5 mg/ml)
MTT in RPMI was added to each well and incubated for 2
hours at 37°C, in the dark. This assay is based on a reac-
tion in which MTT is reduced and converted into purple
formazan only by living cells. After the incubation period,
the media containing MTT was removed, cells were
washed in PBS, and 300 ml DMSO (Fisher Scientific, Pitts-
burgh, PA) was added to each well followed by incubation
for 1 hour at room temperature, on an orbiting shaker
protected from light. Samples were then transferred to 96-
well plate and absorbance at 570 nm was determined
using a Wallac 1420 Victor3V micro-plate reader (Perk-
inElmer, Shelton, CT). Each data point represents three (±
S.D.) independent results; all data points were normal-
ized to un-treated cells.
eGFP gene targeting
Cells grown in complete medium supplemented with
10% FBS and experimental treatment where necessary
were trypsinized and harvested by centrifugation. 2 × 106
cells were resuspended in 100 μl serum-free medium and
transferred to a 4 mm gap cuvette (Fisher Scientific, Pitts-
burgh, PA). The oligonucleotide was added to a final con-
centration of 8 μM and the cells were electroporated (250
V, 13 ms, 2 pulses, 1s interval) using a BTX Electro Square
Porator™ ECM 830 (BTX Instrument Division, Holliston,
MA). The electroporated cells were then transferred to a 60
mm dish, recovered in complete medium supplemented
with 10% FBS, and incubated at 37°C for 24 h prior to
FACS analysis.
Flow cytometry analysis
eGFP fluorescence was measured by a Becton Dickinson
FACScalibur flow cytometer (Becton Dickinson, Franklin
Lakes, NJ). Forty-Eight hours after electroporation, the
cells were harvested and resuspended in FACS buffer
(0.5% BSA, 2 mM EDTA, 2 μg/ml propidium iodide in
PBS) and immediately processed. To analyze cell cycle,
cells were seeded at a density of 1.5 × 106 in a 100 mm
dish in complete medium supplemented with 10% FBS
and the desired concentration of selenomethionine. After
24 h cells were trypsinized, resuspended in 300 μl cold
PBS and fixed by addition of 700 μl cold 95% ethanol.
Cells were incubated a 4°C for 16 hours, subsequently
washed and resuspended in 500 μl of PBS containing 50
μg/ml propidium iodide and analyzed by FACScalibur for
DNA content.
Pulsed-field gel electrophoresis (PFGE)
Cells were seeded at a density of 1.5 × 106 in a 100 mm
dish in complete medium supplemented with 10% FBS
and selenomethionine at concentrations of 0, 100, 200,
and 400 μM respectively, or MMS at 150 μM to serve as a
positive control. After 24 h, the cells were trypsinized and
1 × 106 cells were melted in 1% low melt agarose (GIBCO,
Invitrogen, Carlsbad, CA) in 50 mM EDTA. These agarose
inserts were incubated in 50 mM EDTA, 1% N-laurosylsar-
cosine, 1 mg/ml proteinase K at 50°C, shaking, for 48
hours and subsequently washed four times in 1X TE buffer
before loading onto a 1% pulsed field certified agarose gel
(Bio-Rad, Hercules, CA). Samples were separated by elec-
trophoresis for 24 h using a 120° field angle, 60 to 240s
switch time, 4 V/cm (Bio-Rad, Hercules, CA), and visual-
ized by ethidium bromide staining on an AlphaImager
2200 (Alpha Innotech Corp., San Leandro, CA).BMC Molecular Biology 2007, 8:7 http://www.biomedcentral.com/1471-2199/8/7
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Western blot analyses
Cell extracts were prepared 24 h after the plasmids were
introduced to the cells by electroporation. The cells were
first washed with PBS and then suspended in lysis buffer
(25 mM Tris, pH 7.5, 5 mM EDTA, 600 mM NaCl, 1 mM
DTT, 0.1% NP40, 5 μg/ml leupeptin, 2 μM pepstatin, 1
mM PMSF, 10% glycerol) and incubated for 30 min fol-
lowed by centrifugation at 15,000 × g for 30 min. The
supernatant was analyzed for protein concentration using
the BioRad Protein Assay. Proteins were separated on a
10% SDS-PAGE gel and electroblotted to a nitrocellulose
membrane (BioRad, Richmond, CA). The membrane was
incubated with α-p53 (DO-1), a mouse monoclonal anti-
body against total (wild-type and mutant) human p53
(Santa Cruz Inc., Santa Cruz, CA) at a 1:200 dilution. The
secondary antibody, a bovine anti-mouse horse radish
peroxidase conjugated-antibody (Santa Cruz Inc., Santa
Cruz, CA) was used to visualize the primary reaction at a
1:5000 dilution, followed by the addition of Chemilumi-
nescence ECL™ Reagents (Amersham, Piscataway, NJ) and
hyperfilm (Kodak). Activated p53 was detected by α-p53
Ser15 (PC386, Calbiochem, San Diego, CA) at a 1:1000
dilution, visualized by a goat α-rabbit secondary at a
1:2000 dilution. Ref-1 protein was detected using the Ref-
1 (C-20): sc-334 affinity purified rabbit polyclonal anti-
body (Santa Cruz Inc., Santa Cruz, CA) at a 1:400 dilu-
tion; visualized by a goat α-rabbit secondary at a 1:2000
dilution. Actin expression was used as an internal control
to normalize for protein levels; a goat β-actin antibody
(Santa Cruz Inc., Santa Cruz, CA) in a 1:500 dilution, vis-
ualized by anti-goat IgG-HRP (Sigma, St. Louis, MI) with
the Chemiluminescence ECL™ Reagents.
Abbreviations
Selenomethionine (SeMet); Homologous recombination
(HR); Pulsed-field gel electrophoresis (PFGE).
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